The shares are no use until they start generating revenues in the US.
Performance does not include any revenue to date its from 2020 july
basically unless the US team pulls some of these licencing deals out there bum ... no cash ... no shares
and we all agree how transformative US licencing deals will be for zelira as it prooves US licencing footprint ontop of global launch strategies
bottom line the shares align with investor interests.
- Forums
- ASX - By Stock
- Ann: Director Performance Rights
The shares are no use until they start generating revenues in...
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add ZLD (ASX) to my watchlist
|
|||||
Last
35.0¢ |
Change
0.020(6.06%) |
Mkt cap ! $3.744M |
Open | High | Low | Value | Volume |
33.0¢ | 35.0¢ | 33.0¢ | $1.085K | 3.215K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 8629 | 35.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
37.5¢ | 118 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 9841 | 0.350 |
3 | 8703 | 0.330 |
2 | 1708 | 0.305 |
1 | 5000 | 0.300 |
2 | 12857 | 0.290 |
Price($) | Vol. | No. |
---|---|---|
0.375 | 118 | 2 |
0.380 | 675 | 2 |
0.390 | 218 | 1 |
0.400 | 115 | 1 |
0.410 | 3837 | 2 |
Last trade - 15.45pm 03/07/2024 (20 minute delay) ? |
Featured News
ZLD (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham, CEO
James Graham
CEO
Previous Video
Next Video
SPONSORED BY The Market Online